David Lebwohl - Jan 1, 2022 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Medical Officer
Signature
James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jan 1, 2022
Transactions value $
-$117,964
Form type
4
Date filed
3/3/2022, 07:00 PM
Previous filing
Nov 9, 2021
Next filing
Mar 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Options Exercise +3.19K +36.27% 12K Jan 1, 2022 Direct F1, F2
transaction NTLA Common Stock Sale -$118K -1.05K -8.78% $112.24 10.9K Jan 1, 2022 Direct F3
transaction NTLA Common Stock Award $0 +13.8K +126.5% $0.00 24.7K Mar 1, 2022 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Restricted Stock Unit Options Exercise $0 -3.19K -25% $0.00 9.56K Jan 1, 2022 Common Stock 3.19K Direct F1, F5
transaction NTLA Stock Option (right to buy) Award $0 +13.8K $0.00 13.8K Mar 1, 2022 Common Stock 13.8K $79.85 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 Includes 72 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2021.
F3 Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022.
F4 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F5 On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.
F6 This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.